Astria Therapeutics, Inc. Common Stock
ATXSAstria Therapeutics, Inc. (ATXS) is a biotechnology company focused on developing treatments for rare autoimmune and allergic diseases. The company specializes in innovative therapies aimed at addressing unmet medical needs, particularly in the fields of immunology and inflammation.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| February 28, 2005 | $0.40 | 2005-03-29 | 2004-12-31 |
| February 28, 2004 | $0.36 | 2004-03-18 | 2003-12-31 |
Dividends Summary
- Consistent Payer: Astria Therapeutics, Inc. Common Stock has rewarded shareholders with 2 dividend payments over the past 1 years.
- Total Returned Value: Investors who held ATXS shares during this period received a total of $0.76 per share in dividend income.
- Latest Payout: The most recent dividend of $0.40/share was paid 7634 days ago, on February 28, 2005.
- Dividend Growth: Since 2004, the dividend payout has grown by 11.1%, from $0.36 to $0.40.
Company News
Investor rights law firm Halper Sadeh LLC is investigating three companies for potential federal securities law violations and breaches of fiduciary duties related to their merger transactions: Astria Therapeutics' sale to BioCryst Pharmaceuticals, Green Dot Corporation's sale to Smith Ventures and CommerceOne Financial Corporation, and United Se...
Law firm investigating potential securities law violations and fiduciary duty breaches for multiple companies involving merger and acquisition transactions.
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involving mergers and acquisitions.
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches in several corporate sales involving trueCar, Akero Therapeutics, PotlatchDeltic, and Astria Therapeutics.
BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics for $700 million, adding a new product candidate (Navenibart) for hereditary angioedema treatment, with the deal expected to close in Q1 2026.
